ArticleReceptors & clinical investigation2016
Physiological role of receptor activator nuclear factor-kB (RANK) in denervation-induced muscle atrophy and dysfunction.
Article in Receptors & clinical investigation, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 15 citations in OpenAlex.
- Trial
- Morphological and functional phenotyping of skeletal muscle and bone in the zQ175 knock-in mouse model of Huntington's disease.Journal of Huntington's disease · 2026Article
- Denosumab's Therapeutic Effect for Future Osteosarcopenia Therapy : A Systematic Review and Meta-Analysis.Annals of geriatric medicine and research · 2023Article
- The SarcoEndoplasmic Reticulum Calcium ATPase (SERCA) pump: a potential target for intervention in aging and skeletal muscle pathologies.Skeletal muscle · 2021Review
- Is there a potential dual effect of denosumab for treatment of osteoporosis and sarcopenia?Clinical rheumatology · 2021Article
- The Role of Osteokines in Sarcopenia: Therapeutic Directions and Application Prospects.Frontiers in cell and developmental biology · 2021Review
- l-Cysteine and Vitamin D Co-Supplementation Alleviates Markers of Musculoskeletal Disorders in Vitamin D-Deficient High-Fat Diet-Fed Mice.Nutrients · 2020Article
- Myokines and Osteokines in the Pathogenesis of Muscle and Bone Diseases.Current osteoporosis reports · 2020Review
- A Pooled Analysis of Fall Incidence From Placebo-Controlled Trials of Denosumab.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2020Article
- Commentary on the effects of receptor activator of nuclear factor-B ligand inhibition on bone mass and muscle strength.Journal of diabetes investigation · 2020Article
- RANKL inhibition improves muscle strength and insulin sensitivity and restores bone mass.The Journal of clinical investigation · 2019Article
- Therapeutic approaches to osteosarcopenia: insights for the clinician.Therapeutic advances in musculoskeletal disease · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
The bone remodeling and homeostasis are mainly controlled by the receptor-activator of nuclear factor kB (RANK), its ligand RANKL, and the soluble decoy receptor osteoprotegerin (OPG) pathway. While there is a strong association between osteoporosis and skeletal muscle dysfunction, the functional relevance of a particular biological pathway that synchronously regulates bone and skeletal muscle physiopathology remains elusive. Our recent article published in the American Journal of Physiology (Cell Physiology) showed that RANK is also expressed in fully differentiated C2C12 myotubes and skeletal muscles. We used the Cre-Lox approach to inactivate muscle RANK (RANK
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.